CRISPR pioneer Jennifer Doudna, Ph.D., looks set to continue to push the boundaries of gene editing, as she announces plans to team up with life sciences giant Danaher to create a center focused on generating new therapies for rare and other diseases. The center,...
On December 8, 2023, the U.S. Food and Drug Administration (FDA) approved two innovational gene therapies, Casgevy and Lyfgenia, for treating sickle cell disease (SCD) in patients aged 12 and older. This marks the first approval of cell-based gene therapies for SCD,...
Days away from an FDA decision on a sickle cell gene therapy, CRISPR Therapeutics is ditching its “first-generation” allogeneic CAR-T candidates and expanding into autoimmune disease. The pipeline update is the latest internal changes to come to the surface at the...
The FDA has three target action dates on the books during the next two weeks, including one potentially industry-transforming decision for a CRISPR-based gene therapy. Vertex, CRISPR Eye Landmark Gene Therapy Approval In one of the year’s most highly...
Feng Zhang lab’s recent work published in Science introduces a novel algorithm, fast locality-sensitive hashing-based clustering (FLSHclust), designed for mining large sequencing databases. This approach aims to address the limitations of existing methods in...
